Key result
Novel cyclic peptides fully disrupt the PCSK9-LDLR interaction in preclinical assays.
Answers are grounded in this paper and cite their sources.
The discovery of truncated cyclic peptides that disrupt PCSK9/LDL-R interaction provides a pathway toward developing oral small molecule PCSK9 inhibitors.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDL-R) degradation. We previously identified and optimized 13-mer cyclic peptides that bind to a novel, induced-fit pocket adjacent to the binding interface of PCSK9 and LDL-R and effectively disrupted the PCSK9/LDL-R protein-protein interaction (PPI) both in vitro and in vivo. However this series of large cyclic peptides required charged groups for function and lacked oral bioavailability in rodents. We describe herein multiple structure-based modifications to these original peptides to yield truncated, neutral molecules with full PPI function in both biochemical and cellular assays. In parallel, new mRNA-peptide display screens identified non-functional 8- and 9-mer compounds which ligand the induced-fit pocket in a distinct manner. Taken together, these studies indicate multiple directions to reduce the size and complexity of this peptide class toward a true small molecule oral agent.
No takes yet. Share an insight, caveat, or question.
Grosche et al. (2024) studied this question. Truncated cyclic peptides was evaluated on PCSK9/LDL-R protein-protein interaction disruption. Truncated, neutral cyclic peptides targeting an induced-fit pocket on PCSK9 demonstrated full protein-protein interaction disruption function in biochemical and cellular assays.
Synapse has enriched 10 related papers. Consider them for comparative context: